Drug-eluting stents during ST-segment elevation acute myocardial infarction: a critical analysis.

Abstract

Primary percutaneous coronary intervention is the preferred reperfusion therapy for ST-segment elevation acute myocardial infarction patients within 12 hours of symptom-onset. Routine stent implantation during the procedure significantly reduces the rate of target vessel revascularization, although restenosis still represents a current limitation of the technique. Drug-eluting stents were developed to treat and prevent coronary restenosis. Randomized trials, meta-analysis, and registries proved their efficacy and safety in different clinical situations, including acute myocardial infarction. However, the increased risk of late stent thrombosis associated with drug-eluting stents during primary percutaneous coronary interventions encourages a careful analysis to identify which patients most benefit from them, as well as those where a prolonged dual antiplatelet therapy does not represent a limiting factor.

• Authors: Pedro Beraldo de Andrade, Marden André Tebet, Felipe Souza Maia da Silva, Mônica Vieira Athanazio de Andrade, André Labrunie, Luiz Alberto Piva e Mattos
• Journal: Journal of interventional cardiology (J Interv Cardiol) Vol. 24 Issue 5 Pg. 416-23 (Oct 2011) ISSN: 1540-8183 [Electronic] United States
• PMID: 21539610 (Publication Type: Journal Article, Review)
• Copyright: ©2011, Wiley Periodicals, Inc.

Topics

• Angioplasty, Balloon, Coronary (methods)
• Coronary Restenosis (prevention & control)
• Drug-Eluting Stents
• Humans
• Myocardial Infarction (pathology, therapy)
• Risk Assessment
• Time Factors